Task order 75N93022F00001 base award
Active Awarded Last action
- Contract number
- 75N93022F00001
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $905,501
Award facts
- Opportunity
-
- Early Phase Clinical Trial Units (EPCTU) Pre-Solicitation · 75N93020R00023 · Posted Nov 19, 2020
- Contract value 49% obligated
-
- $905,501.00 Current, with exercised options
- $1,859,402.00 Potential, with all options
- Completion date 48% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cape Fear, NC 28401, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $183,478 | |
| Supplemental Agreement for work within scope | $183,411 | |
| Exercise an Option | $182,396 | |
| Exercise an Option | $179,268 | |
| Original award | $176,948 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $1.86 million cost-plus-fixed-fee task order (75N93022F00001) to PPD Development LP for administration and overall clinical operations support and concept development under the Early Phase Clinical Trial Units (EPCTU) indefinite delivery/indefinite quantity contract. The task order, issued on January 14, 2022, with an ultimate completion date of January 13, 2032, represents the base award for clinical trial management and operational support services. PPD Development LP, a globally recognized contract research organization and subsidiary of Thermo Fisher Scientific headquartered in Wilmington, North Carolina, was selected without a set-aside designation to leverage its extensive experience supporting NIAID's infectious disease research portfolio and clinical trial infrastructure.
This task order falls under NIAID's broader $346.6 million EPCTU multiple-award contract for Phase 0 through Phase II clinical trial services, positioning PPD Development LP to provide mission-critical operational, administrative, and regulatory support essential to federal infectious disease research programs. The company's selection reflects its substantial track record managing complex, multi-site clinical trials and supporting NIAID's Division of AIDS and other research divisions. PPD Development LP maintains an extensive portfolio of federal research contracts and indefinite delivery vehicles totaling hundreds of millions of dollars across the National Institutes of Health, Department of Defense, and other federal agencies, demonstrating its capacity to deliver comprehensive clinical research support services aligned with federal research priorities.
Quick answers
Who was awarded contract 75N93022F00001?
75N93022F00001 was awarded to PPD Development LP by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 14, 2022.
How much is contract 75N93022F00001 worth?
The government has obligated $905,501 on 75N93022F00001. Its potential value, with all options, is $1,859,402.
Is contract 75N93022F00001 an order under another contract?
Yes. 75N93022F00001 is a delivery order under 75N93022D00017, an indefinite delivery contract, on Early Phase Clinical Trial Units (EPCTU).
Was contract 75N93022F00001 competed?
The extent of competition for 75N93022F00001 was full and open competition. The government received 6 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award